Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002631 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 298
- Enrollment target
NCT00002631 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 298 participants.
The verdict
NCT00002631, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 298 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not known whether high-dose radiation therapy is more effective than standard dose radiation therapy in treating cancer of the esophagus. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy plus high- or standard-dose radiation therapy in treating patients with cancer of the esophagus.
Interventions
- DRUG cisplatin
- DRUG fluorouracil
- DRUG chemotherapy
- RADIATION low-LET electron therapy
- RADIATION low-LET photon therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 1995-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002631
The ClinicalTrials.gov registry entry for NCT00002631 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00002631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002631 about?
NCT00002631 is a clinical study titled "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not known whether high-dose radiation therapy is more effective than standard dose radiation therapy in treat...
What is the current status of trial NCT00002631?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 298 participants. The study started on 1995-06.
What interventions are being tested in trial NCT00002631?
The interventions under investigation include: cisplatin (DRUG), fluorouracil (DRUG), chemotherapy (DRUG), low-LET electron therapy (RADIATION), low-LET photon therapy (RADIATION).
Who is sponsoring clinical trial NCT00002631?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.